EGFR+ Lung Cancer

Evaluating the Role of EGFR Mutations in the Treatment of Advanced NSCLC

July 09, 2020

Balazs Halmos, MD, MS, discusses the role of EGFR mutations in patients with advanced non—small cell lung cancer.

Correlation Between ctDNA Clearance and PFS Improvement Demonstrated in EGFR+/MET+ NSCLC

June 23, 2020

MET amplifications are found in up to 10% of patients with EGFR-mutant NSCLC who progress on first- or second-generation EGFR TKIs and in up to 25% of those who progress on a third-generation EGFR TKIs, necessitating the need for treatment options in the population.

EGFR TKIs Excite Treatment Landscape of EGFR-Mutant Lung Cancers

June 22, 2020

Julia K. Rotow, MD, discusses the excitement of EGFR tyrosine kinase inhibitors for the treatment of patients with EGFR-mutant lung cancers.

Amivantamab Generates Activity With Manageable Toxicity in EGFR Exon 20-Mutant NSCLC

June 05, 2020

Amivantamab (JNJ-61186372) induced durable responses and demonstrated a manageable safety profile in patients with EGFR exon 20-mutant non–small cell lung cancer (NSCLC), according to results from the phase I CHRYSALIS study (NCT02609776) presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program.

Clinical Activity Shown with Poziotinib in NSCLC and EGFR exon 20

June 04, 2020

In a subgroup analysis of cohort 1 of the phase 2 ZENITH20 study, patients with previously treated non-small cell lung cancer and EGFR exon 20 insertions demonstrated clinical activity when receiving poziotinib, including those with central nervous system metastatic disease, which was not impacted by prior lines of therapy.

Elevated Dose of Osimertinib Induced Clinical Activity in EGFR Exon 20-Mutant NSCLC

June 02, 2020

A daily dose of osimertinib at 160 mg was well-tolerated with clinical activity observed in patients with EGFR exon 20-mutant non–small cell lung cancer, according to results from the phase 2 ECOG-ACRIN 5162 trial.

High-Dose Osimertinib Shows Limited Benefit in EGFR+ NSCLC With CNS Involvement

June 02, 2020

Treatment with high-dose osimertinib showed positive survival and central nervous system progressive disease control in a real-world cohort of patients with EGFR-mutant non–small cell lung cancer, but these results were not statistically significant.

FDA Approves Frontline Ramucirumab/Erlotinib for EGFR+ mNSCLC

May 30, 2020

The FDA has approved ramucirumab in combination with erlotinib for the first-line treatment of patients with metastatic non–small cell lung cancer harboring EGFR exon 19 deletions or exon 21 mutations.

Adjuvant Osimertinib Leads to Significant Boost in DFS in Early-Stage EGFR+ NSCLC

May 28, 2020

"Adjuvant osimertinib is the first targeted agent in a global randomized trial to show a statistically significant and clinically meaningful improvement in disease-free survival in patients with stage IB/II/IIIA EGFR mutation–positive non–small cell lung cancer."

FLAURA Trial Demonstrates Efficacy in EGFR-Positive Lung Cancer

May 06, 2020

Suresh S. Ramalingam, MD, discusses the phase III FLAURA trial.